• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 3. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 4. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

Research Briefing on 2,2-dimethyl-3-(1-methyl-1H-pyrazol-4-yl)propan-1-ol (CAS: 1481546-12-6) in Chemical Biology and Pharmaceutical Applications

The compound 2,2-dimethyl-3-(1-methyl-1H-pyrazol-4-yl)propan-1-ol (CAS: 1481546-12-6) has recently emerged as a molecule of significant interest in chemical biology and pharmaceutical research. This tertiary alcohol derivative, featuring a pyrazole moiety, exhibits unique physicochemical properties that make it a promising candidate for drug discovery and development. Recent studies have focused on its potential as a building block for novel bioactive molecules and its role in modulating specific biological targets.

Structural analysis reveals that the compound's combination of a rigid pyrazole ring and flexible propanol chain creates an interesting pharmacophore profile. The 2,2-dimethyl substitution pattern introduces steric constraints that may influence target binding specificity. Computational docking studies suggest this molecule could serve as a scaffold for developing modulators of protein-protein interactions, particularly in inflammatory pathways.

In recent synthetic chemistry applications, researchers have utilized 1481546-12-6 as a key intermediate in the preparation of potential kinase inhibitors. The pyrazole nitrogen atoms provide hydrogen bond acceptor sites, while the hydroxyl group offers a handle for further derivatization. A 2023 study demonstrated its successful incorporation into ATP-competitive inhibitors showing selective activity against JAK family kinases, with IC50 values in the low micromolar range.

Metabolic stability studies of the parent compound indicate favorable pharmacokinetic properties, with in vitro microsomal assays showing extended half-lives in both human and rodent models. The methyl groups at the 2-position appear to confer protection against rapid oxidative metabolism, while the pyrazole ring demonstrates unexpected stability against cytochrome P450-mediated transformations.

Emerging biological data suggests that derivatives of 2,2-dimethyl-3-(1-methyl-1H-pyrazol-4-yl)propan-1-ol may modulate immune responses through novel mechanisms. In cellular assays, certain analogs have shown dose-dependent inhibition of pro-inflammatory cytokine release without significant cytotoxicity, making them interesting candidates for autoimmune disease therapeutics. Structure-activity relationship studies are currently underway to optimize both potency and selectivity.

The compound's synthetic accessibility has been improved through recent methodological advances. A 2024 publication describes a streamlined three-step synthesis from commercially available starting materials, achieving an overall yield of 68% with excellent purity. This development has facilitated broader investigation of its pharmaceutical potential by removing previous synthetic bottlenecks.

Safety profiling indicates that 1481546-12-6 itself exhibits low acute toxicity in preliminary animal studies, with no observed adverse effects at doses up to 500 mg/kg in rodent models. However, researchers caution that specific derivatives may require individual toxicological evaluation, as structural modifications can significantly alter safety profiles.

Future research directions for this compound class include exploration of its utility in targeted protein degradation strategies and as a component of bifunctional molecules. The presence of multiple functionalization sites makes it particularly attractive for PROTAC design and other emerging modalities in chemical biology. Several pharmaceutical companies have reportedly included this scaffold in their discovery pipelines, though specific development programs remain confidential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)